Lancet Respiratory Medicine

Papers
(The H4-Index of Lancet Respiratory Medicine is 85. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Savolitinib in NSCLC: progress in the MET exon 14 journey1157
US Senate committee investigates asthma inhaler prices528
Concerns regarding a suggested long COVID paradigm – Authors' reply425
Broad protection from SARS-CoV-2 variants without antigen matching327
European Respiratory Society International Congress 2022276
European Society of Intensive Care Medicine (ESICM) LIVES 35th Annual Congress264
Opioids bring peace to patients with IPF cough249
Video laryngoscopy is not the nemesis of direct laryngoscopy246
Impact of Myanmar's earthquake on respiratory health239
Predatory publishers appear in PubMed (and your inbox)232
Risk factors for COVID-19-associated pulmonary aspergillosis: a systematic review and meta-analysis220
FLiRTing with danger as SARS-CoV-2 variants evolve213
Thoracentesis: an old story and some new sources207
Chronic obstructive pulmonary disease: 10 years of precision-guided success205
Correction to Lancet Respir Med 2024; 12: 129–40201
Australia bans engineered stone to prevent silicosis200
Interstitial lung disease: a decade of progress and hope200
The burden of tuberculosis in Libya194
Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials192
Rethinking the role of procalcitonin in suspected sepsis191
First results from the international paediatric bronchiectasis registry (Child-BEAR-Net Registry) describing multicountry variations in childhood bronchiectasis and its management: a multicentre, cros189
Predicted bodyweight—a misleading metric for tidal volume titration?185
Chronic respiratory diseases in Asia: time for action185
Major gaps in childhood pneumonia research priorities remain182
Bedaquiline, pretomanid, and linezolid with or without moxifloxacin for tuberculosis177
Top ten research priorities for breathlessness research: UK James Lind Alliance priority setting partnership172
Rituximab for connective tissue disease-associated interstitial lung disease172
Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial163
Optimising trial design for cardiogenic shock: insights from the sixth Critical Care Clinical Trialists Workshop158
Long COVID: systemic inflammation and obesity as therapeutic targets158
Concerns about PRISm156
Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study156
Overcoming barriers to scaling up tuberculosis preventive treatment for household contacts147
Challenges of modulating the risk of bronchopulmonary dysplasia in clinical trials147
Ceftriaxone to prevent early ventilator-associated pneumonia in patients with acute brain injury: a multicentre, randomised, double-blind, placebo-controlled, assessor-masked superiority trial143
First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, m143
Association of SARS-CoV-2 infection and persistence with long COVID134
Effectiveness of preventive treatment among different age groups and Mycobacterium tuberculosis infection status: a systematic review and individual-participant data meta-analysis of contact tracing s134
Perioperative lung expansion and pulmonary outcomes after open abdominal surgery versus usual care in the USA (PRIME-AIR): a multicentre, randomised, controlled, phase 3 trial132
Preoxygenation strategies for intubation of patients who are critically ill: a systematic review and network meta-analysis of randomised trials132
Endotracheal surfactant for infants with life-threatening bronchiolitis (BESS): a randomised, blinded, sham-controlled, phase 2 trial131
Transbronchial cryobiopsy followed by as-needed surgical lung biopsy versus immediate surgical lung biopsy for diagnosing interstitial lung disease (the COLD study): a randomised controlled trial128
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, doub127
Non-invasive respiratory supports and criteria for intubation in randomised trials of acute hypoxaemic respiratory failure: a systematic review and network meta-analysis126
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, co123
Health effects of gas fuels: interpreting evidence from a comprehensive meta-analysis120
Sarcoidosis and fatigue: there is a useful cognitive treatment? – Authors' reply119
Claudio Castanos—leader in cystic fibrosis care in Argentina114
Nasally delivered SARS-CoV-2 vaccines: future promise and challenges113
Solid and semi-solid perspectives in thoracic surgery113
Priorities for NICE in health and social care113
Patient with cystic fibrosis not diagnosed until age 23 years now treated with the new triple therapy Trikafta112
Genetic associations and lung function in IPF: unexpected answers, persistent questions112
Comparative vaccine effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study111
Extracorporeal cardiopulmonary resuscitation: not why, but how109
Trump administration decimates worker health oversight109
Correction to Lancet Respir Med 2022; 10: 972–84107
Correction to Lancet Respir Med 2021; 9: 1275–87107
Correction to Lancet Respir Med 2025; 13: 244–55106
Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis104
Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis103
Evaluation of the effect of multimorbidity on difficult-to-treat asthma using a novel score (MiDAS): a multinational study of asthma cohorts103
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CRO100
Lung epithelial and myeloid innate immunity in influenza-associated or COVID-19-associated pulmonary aspergillosis: an observational study100
Chronic cough as a disease: implications for practice, research, and health care99
Health effects from climate-driven events: lessons learnt98
Choice overload for RSV prevention—how to form your opinion97
Spirometry in female individuals – Authors' reply97
Unavailability of varenicline: a global tragedy for the fight against the tobacco epidemic96
Developments and priorities in bronchiectasis research95
Pre-COPD: an evolving concept with practice potential94
Management after combined BPA and medical therapy in CTEPH: time for cardiopulmonary exercise testing93
The Ramp to Nowhere: When hope slips through the cracks in care93
Realignment of clinical research after the COVID-19 era93
Tackling tuberculosis: what lies beneath the surface?91
NICE guidance on nivolumab plus ipilimumab for untreated, unresectable malignant pleural mesothelioma91
Determinants of long-term outcomes in patients with COVID-19 supported with ECMO90
COP27 Climate Change Conference: urgent action needed for Africa and the world89
Underappreciated causes of obstructive lung disease89
Trouble with promoting lung cancer screening in never-smokers88
COPD: a complex, multifactorial, but preventable disease?88
Liberal or restrictive transfusion for VV ECMO88
Clean air, climate targets, and respiratory health in Europe88
Unveiling a hidden phenotype of early tuberculosis86
Correction to Lancet Respir Med 2023; 11: 1064–7486
0.28093504905701